Detalles de la búsqueda
1.
Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings.
J Infect Dis
; 226(3): 374-385, 2022 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35668702
2.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
BMC Infect Dis
; 20(1): 426, 2020 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32552685
3.
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
BMC Infect Dis
; 13: 116, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23510357
4.
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
Eur J Pediatr
; 172(5): 601-12, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23307281
5.
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children.
J Pediatric Infect Dis Soc
; 12(5): 273-281, 2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37142551
6.
Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.
Hum Vaccin
; 7(2): 239-47, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21343698
7.
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
BMJ Open
; 9(8): e023502, 2019 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31462457
8.
Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014.
Dermatol Ther (Heidelb)
; 9(1): 117-133, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30456446
9.
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
BMJ Open
; 8(6): e020528, 2018 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880565
10.
Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
Hum Vaccin Immunother
; 13(3): 636-644, 2017 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28152332
11.
Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
Hum Vaccin Immunother
; 12(1): 132-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26575983
12.
Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Hum Vaccin Immunother
; 12(8): 2162-2168, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27152501
13.
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Pediatr Infect Dis J
; 34(12): e298-307, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26780033
14.
Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
Vaccine
; 33(7): 933-41, 2015 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25152325
15.
Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
Vaccine
; 33(7): 924-32, 2015 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25305567
16.
Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age.
J Pediatric Infect Dis Soc
; 3(1): 33-42, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24567843
17.
Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
Int J Infect Dis
; 17(3): e173-6, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23246368
18.
Persistence clinical studies: can you believe what you see?
Hum Vaccin Immunother
; 9(6): 1351-7, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23857273
19.
Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Drugs Aging
; 30(5): 309-19, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23494214
20.
Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.
Clin Vaccine Immunol
; 20(10): 1499-507, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23885033